For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Dr. Daniel Meltzer, a weight loss expert, suggests that it's possible to maintain weight loss after using GLP-1 medications by creating proper habits, including exercise and eating well. He emphasizes ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...

including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs. However, the new study led by Ziyad Al-Aly, a physician-scientist at the Veterans Affairs St ...